RxDoctor Payments Data

Jill Jones, PA

Physician Assistant · Laguna Niguel, CANPI 1164630901

Payments from drug & device makers

$10,189in general payments, 2019–2025

Across 477 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$850
  • Abbott$668
  • Amgen$661
  • AstraZeneca$647
  • plus $5K from 42 others

What the payments were for

  • Travel & lodging$80%
  • Food & beverage$10,175100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,189 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$81,036
Medicare patients
252
Services billed
2,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$35,357
JardianceEmpagliflozin20$29,891
MounjaroTirzepatide12$20,065
KerendiaFinerenone19$14,629
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,438
SynthroidLevothyroxine Sodium25$1,936
Ezetimibe26$1,362
Sumatriptan Succinate15$1,106
Levothyroxine Sodium71$872
Rosuvastatin Calcium56$753
Atorvastatin Calcium72$700
Lisinopril43$383
Olmesartan Medoxomil12$355
Losartan Potassium31$323
Albuterol Sulfate HfaAlbuterol Sulfate15$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$850$35,35726 claims
Boehringer IngelheimJardiance$549$29,89120 claims
Lilly USA, LLCMounjaro$1,337$20,06512 claims
BayerKerendia$534$14,62919 claims
AbbVieSynthroid$1,343$1,93625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Laguna Niguel

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →